ono-4059
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01659255)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544928 ↗
Also known as
- gs-4059
- gs-4059
- gs-4059
- ono-4059
- ono-4059
- ono-4059
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02626026 | Phase 1 | Jan 1, 2016 | Gilead Sciences |
| NCT01659255 | Phase 1 | Aug 1, 2012 | Gilead Sciences, Ono Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 2 | 2 | 1 | 2012 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1